Eloralintide
Research chemical · Grade C
Goals
weight-loss
Evidence
1 RCT / 1 animal / 1 in vitro
Routes
injectable-sc
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
pharmacokinetics consistent with once-weekly dosing (half-life ~7 days from albumin-bound lipidated structure)
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.